Makers Laboratories Ltd

Makers Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 May 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 29 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Makers Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from a very expensive to a fair valuation grade. This change, coupled with a recent upgrade in its Mojo Grade from Sell to Hold, highlights a renewed price attractiveness for investors within the Pharmaceuticals & Biotechnology sector. A detailed analysis of its price-to-earnings (P/E) and price-to-book value (P/BV) ratios against historical and peer benchmarks reveals the evolving investment narrative for this micro-cap stock.

Makers Laboratories Ltd., a micro-cap pharmaceutical formulations manufacturer with a market capitalisation of ₹99.00 crores, reported consolidated net profit of ₹1.09 crores for Q4 FY26, marking a dramatic recovery from the previous quarter's ₹0.94 crores but raising questions about sustainability. The stock surged 2.63% to ₹165.55 in Monday's trading session, reflecting investor optimism despite persistent structural challenges that have plagued the company's long-term performance.

With a decisive surge to Rs 174 on 20 May 2026, Makers Laboratories Ltd has reached a fresh 52-week high, marking a notable milestone in its price momentum. This advance comes amid a backdrop of mixed market conditions, underscoring the stock’s relative strength and technical resilience.

Makers Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 May 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Makers Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in technical indicators and recent financial results. Despite lingering concerns over valuation and long-term fundamentals, the stock’s enhanced momentum and quarterly performance have prompted a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector.

Makers Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Apr 2026. However, the analysis below reflects the stock's current position as of 03 May 2026, incorporating the latest fundamentals, returns, and financial metrics to provide investors with an up-to-date perspective.

Makers Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 20 Apr 2026. This shift reflects a complex interplay of deteriorating financial fundamentals, expensive valuation metrics, and a nuanced technical outlook, despite some recent positive quarterly performance. The downgrade comes amid a 2.25% decline in the stock price, signalling investor caution.

Makers Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in technical indicators and recent financial performance. The upgrade, effective from 8 April 2026, is driven by a combination of bullish technical trends, positive quarterly earnings, and a more favourable valuation outlook despite some lingering fundamental challenges.

Makers Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 2 April 2026. This decision follows a comprehensive reassessment of the company’s quality, valuation, financial trends, and technical indicators, revealing a complex picture of recent performance and outlook.

Makers Laboratories Ltd has seen its investment rating upgraded from Sell to Hold as of 1 April 2026, reflecting a marked improvement in its quarterly financial performance and a reassessment of its valuation and technical outlook. Despite lingering concerns over long-term fundamentals, the company’s recent results and market behaviour have prompted analysts to revise their stance, signalling cautious optimism for investors.

The 50-day moving average for Makers Laboratories Ltd has crossed above the 200-day moving average, signalling a golden cross on 25 Mar 2026. Yet, this technical milestone arrives amid a complex backdrop of conflicting momentum indicators and a micro-cap status that tempers the signal’s reliability.

Makers Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 23 March 2026, driven primarily by a shift in technical indicators despite persistent challenges in valuation and long-term financial fundamentals. The micro-cap pharmaceutical company’s recent quarterly performance showed promising signs, yet its overall financial health and valuation metrics continue to weigh on investor sentiment.

Makers Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 16 Mar 2026, reflecting a deteriorating outlook driven primarily by weakening technical indicators, expensive valuation metrics, and disappointing long-term financial trends despite recent positive quarterly results.

Makers Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 10 Mar 2026, driven primarily by a shift in technical indicators despite ongoing fundamental challenges. The company’s stock price has gained nearly 5% in a single day, reflecting renewed market interest amid mixed signals from financial performance and valuation metrics.

Makers Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 2 March 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the company’s valuation, long-term financial trends, and technical signals have collectively triggered a reassessment of its investment appeal.

Makers Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by improved technical indicators and recent positive quarterly financial results. However, the company continues to face challenges in valuation and long-term fundamental strength, prompting a cautious stance despite short-term momentum gains.